Search

Your search keyword '"Zeidner, Joshua F"' showing total 432 results
Start Over Author "Zeidner, Joshua F"
432 results on '"Zeidner, Joshua F"'

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Author

Xie, Zhuoer, Komrokji, Rami S, Al-Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand A, Saygin, Caner, Zeidan, Amer M, Bewersdorf, Jan Philipp, Mendez, Lourdes M, Kishtagari, Ashwin, Zeidner, Joshua F, Coombs, Catherine C, Madanat, Yazan F, Chung, Stephen S, Badar, Talha, Foran, James M, Desai, Pinkal, Tsai, Charlton, Griffiths, Elizabeth A, Al Malki, Monzr M, Amanam, Idoroenyi, Lai, Catherine, Deeg, H Joachim, Ades, Lionel, Arana-Yi, Cecilia, Osman, Afaf Eg, Dinner, Shira Naomi, Abaza, Yasmin, Taylor, Justin, Chandhok, Namrata S, Soong, Deborah, Brunner, Andrew M, Carraway, Hetty E, Singh, Abhay, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Padron, Eric, Patnaik, Mrinal M, Malcovati, Luca, Savona, Michael R, and Al-Kali, Aref

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 CCUS patients investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count

Published
2024

2. A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Author

Bewersdorf, Jan Philipp, Shallis, Rory M., Sharon, Elad, Park, Silvia, Ramaswamy, Rahul, Roe, Caroline E., Irish, Jonathan M., Caldwell, Anne, Wei, Wei, Yacoub, Abdulraheem, Madanat, Yazan F., Zeidner, Joshua F., Altman, Jessica K., Odenike, Olatoyosi, Yerrabothala, Swaroopa, Kovacsovics, Tibor, Podoltsev, Nikolai A., Halene, Stephanie, Little, Richard F., Piekarz, Richard, Gore, Steven D., Kim, Tae Kon, and Zeidan, Amer M.

Published
2024
Full Text
View/download PDF

3. Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Author

Hoff, Fieke W., Blum, William G., Huang, Ying, Welkie, Rina Li, Swords, Ronan T., Traer, Elie, Stein, Eytan M., Lin, Tara L., Archer, Kellie J., Patel, Prapti A., Collins, Robert H., Baer, Maria R., Duong, Vu H., Arellano, Martha L., Stock, Wendy, Odenike, Olatoyosi, Redner, Robert L., Kovacsovics, Tibor, Deininger, Michael W., Zeidner, Joshua F., Olin, Rebecca L., Smith, Catherine C., Foran, James M., Schiller, Gary J., Curran, Emily K., Koenig, Kristin L., Heerema, Nyla A., Chen, Timothy, Martycz, Molly, Stefanos, Mona, Marcus, Sonja G., Rosenberg, Leonard, Druker, Brian J., Levine, Ross L., Burd, Amy, Yocum, Ashley O., Borate, Uma M., Mims, Alice S., Byrd, John C., and Madanat, Yazan F.

Published
2024
Full Text
View/download PDF

6. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts

Author

Shallis, Rory M, Daver, Naval, Altman, Jessica K, Komrokji, Rami S, Pollyea, Daniel A, Badar, Talha, Bewersdorf, Jan P, Bhatt, Vijaya R, de Botton, Stéphane, de la Fuente Burguera, Adolfo, Carraway, Hetty E, Desai, Pinkal, Dillon, Richard, Duployez, Nicolas, El Chaer, Firas, Fathi, Amir T, Freeman, Sylvie D, Gojo, Ivana, Grunwald, Michael R, Jonas, Brian A, Konopleva, Marina, Lin, Tara L, Mannis, Gabriel N, Mascarenhas, John, Michaelis, Laura C, Mims, Alice S, Montesinos, Pau, Pozdnyakova, Olga, Pratz, Keith W, Schuh, Andre C, Sekeres, Mikkael A, Smith, Catherine C, Stahl, Maximilian, Subklewe, Marion, Uy, Geoffrey L, Voso, Maria Teresa, Walter, Roland B, Wang, Eunice S, Zeidner, Joshua F, Žučenka, Andrius, and Zeidan, Amer M

Published
2023
Full Text
View/download PDF

8. Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy

Author

Hu, Quanyin, Sun, Wujin, Wang, Jinqiang, Ruan, Huitong, Zhang, Xudong, Ye, Yanqi, Shen, Song, Wang, Chao, Lu, Weiyue, Cheng, Ke, Dotti, Gianpietro, Zeidner, Joshua F, Wang, Jun, and Gu, Zhen

Subjects
Engineering, Biomedical Engineering, Stem Cell Research, Stem Cell Research - Nonembryonic - Non-Human, Hematology, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Cancer, Blood, Animals, Antibodies, Blood Platelets, Cell Line, Tumor, Chemokines, Cytokines, Disease Models, Animal, Female, Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cells, Leukemia, Mice, Mice, Inbred C57BL, Mice, Knockout, Programmed Cell Death 1 Receptor, T-Lymphocytes, Biomedical engineering
Abstract

Patients with acute myeloid leukaemia who relapse following therapy have few treatment options and face poor outcomes. Immune checkpoint inhibition, for example, by antibody-mediated programmed death-1 (PD-1) blockade, is a potent therapeutic modality that improves treatment outcomes in acute myeloid leukaemia. Here, we show that systemically delivered blood platelets decorated with anti-PD-1 antibodies (aPD-1) and conjugated to haematopoietic stem cells (HSCs) suppress the growth and recurrence of leukaemia in mice. Following intravenous injection into mice bearing leukaemia cells, the HSC-platelet-aPD-1 conjugate migrated to the bone marrow and locally released aPD-1, significantly enhancing anti-leukaemia immune responses, and increasing the number of active T cells, production of cytokines and chemokines, and survival time of the mice. This cellular conjugate also promoted resistance to re-challenge with leukaemia cells. Taking advantage of the homing capability of HSCs and in situ activation of platelets for the enhanced delivery of a checkpoint inhibitor, this cellular combination-mediated drug delivery strategy can significantly augment the therapeutic efficacy of checkpoint blockade.

Published
2018

10. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Author

Lachowiez, Curtis A., Ravikumar, Vishvaas I., Othman, Jad, O’Nions, Jenny, Peters, Daniel T., McMahon, Christine, Swords, Ronan, Cook, Rachel, Saultz, Jennifer N., Tyner, Jeffrey W., Dillon, Richard, Zeidner, Joshua F., and Pollyea, Daniel A.

Abstract

The European LeukemiaNet 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates reclassification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

Published
2024
Full Text
View/download PDF

11. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Author

Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., and Adès, Lionel

Published
2021
Full Text
View/download PDF

12. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Author

Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, and Mascarenhas, John

Published
2020
Full Text
View/download PDF

14. Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS

Author

Zeidner, Joshua F., Knaus, Hanna A., Zeidan, Amer M., Blackford, Amanda L., Montiel-Esparza, Raul, Hackl, Hubert, Prince, Gabrielle T., Gondek, Lukasz P., Ghiaur, Gabriel, Showel, Margaret M., DeZern, Amy E., Pratz, Keith W., Douglas Smith, B., Levis, Mark J., Gore, Steven, Coombs, Catherine C., Foster, Matthew C., Streicher, Howard, Karp, Judith E., Luznik, Leo, and Gojo, Ivana

Published
2020
Full Text
View/download PDF

17. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia

Author

Rutella, Sergio, Vadakekolathu, Jayakumar, Mazziotta, Francesco, Reeder, Stephen, Yau, Tung-On, Mukhopadhyay, Rupkatha, Dickins, Benjamin, Altmann, Heidi, Kramer, Michael, Knaus, Hanna A., Blazar, Bruce R., Radojcic, Vedran, Zeidner, Joshua F., Arruda, Andrea, Wang, Bofei, Abbas, Hussein A., Minden, Mark D., Tasian, Sarah K., Bornhauser, Martin, Gojo, Ivana, and Luznik, Leo

Subjects
Physiological aspects, Development and progression, Prognosis, Patient outcomes, Health aspects, CD8 lymphocytes -- Physiological aspects -- Health aspects, Immune system -- Health aspects, Acute myelocytic leukemia -- Prognosis -- Development and progression -- Patient outcomes
Abstract

Introduction Acute myeloid leukemia (AML) is a molecularly and clinically heterogeneous disease (1). We recently identified BM microenvironmental transcriptomic profiles that stratify patients with newly diagnosed AML into immune-infiltrated and [...], BACKGROUND. Immune exhaustion and senescence are dominant dysfunctional states of effector T cells and major hurdles for the success of cancer immunotherapy. In the current study, we characterized how acute myeloid leukemia (AML) promotes the generation of senescent-like [CD8.sup.+] T cells and whether they have prognostic relevance. METHODS. We analyzed NanoString, bulk RNA-Seq and single-cell RNA-Seq data from independent clinical cohorts comprising 1,896 patients treated with chemotherapy and/or immune checkpoint blockade (ICB). RESULTS. We show that senescent-like bone marrow [CD8.sup.+] T cells were impaired in killing autologous AML blasts and that their proportion negatively correlated with overall survival (OS). We defined what we believe to be new immune effector dysfunction (IED) signatures using 2 gene expression profiling platforms and reported that IED scores correlated with adverse-risk molecular lesions, stemness, and poor outcomes; these scores were a more powerful predictor of OS than 2017-ELN risk or leukemia stem cell (LSC17) scores. IED expression signatures also identified an ICB-unresponsive tumor microenvironment and predicted significantly shorter OS. CONCLUSION. The IED scores provided improved AML-risk stratification and could facilitate the delivery of personalized immunotherapies to patients who are most likely to benefit. TRIAL REGISTRATION. ClinicalTrials.gov; NCT02845297. FUNDING. John and Lucille van Geest Foundation, Nottingham Trent University's Health & Wellbeing Strategic Research Theme, NIH/NCI P01CA225618, Genentech-imCORE ML40354, Qatar National Research Fund (NPRP8-2297-3-494).

Published
2022
Full Text
View/download PDF

18. A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Author

Zeidner, Joshua F., Lin, Tara L., Vigil, Carlos E., Fine, Gil, Yair Levy, M., Nazha, Aziz, Esteve, Jordi, Lee, Daniel J., Yee, Karen, Dalovisio, Andrew, Wang, Eunice S., Bergua Burgues, Juan M., Schriber, Jeffrey, Litzow, Mark R., Frankfurt, Olga, Castillo, Teresa Bernal Del, Bhatt, Vijaya Raj, Bhatnagar, Bhavana, Mehta, Priyanka, Dillon, Richard, Vicente, Maria Vidriales, Anthony, Stephen, Bearss, David, Montesinos, Pau, and Douglas Smith, B.

Published
2021
Full Text
View/download PDF

22. Comprehensive genomic profiling reveals molecular subsets of ASXL1 -mutated myeloid neoplasms

Author

Johnson, Steven M., primary, Haberberger, James, additional, Galeotti, Jonathan, additional, Ramkissoon, Lori, additional, Coombs, Catherine C., additional, Richardson, Daniel R., additional, Foster, Matthew C., additional, Duncan, Daniel, additional, Montgomery, Nathan D., additional, Ferguson, Naomi L., additional, and Zeidner, Joshua F., additional

Published
2023
Full Text
View/download PDF

23. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Author

Daver, Naval G., primary, Vyas, Paresh, additional, Kambhampati, Suman, additional, Al Malki, Monzr M., additional, Larson, Richard A., additional, Asch, Adam S., additional, Mannis, Gabriel, additional, Chai-Ho, Wanxing, additional, Tanaka, Tiffany N., additional, Bradley, Terrence J., additional, Jeyakumar, Deepa, additional, Wang, Eunice S., additional, Sweet, Kendra, additional, Kantarjian, Hagop M., additional, Garcia-Manero, Guillermo, additional, Komrokji, Rami, additional, Xing, Guan, additional, Ramsingh, Giridharan, additional, Renard, Camille, additional, Zeidner, Joshua F., additional, and Sallman, David A., additional

Published
2023
Full Text
View/download PDF

24. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Author

Sekeres, Mikkael A., Watts, Justin, Radinoff, Atanas, Sangerman, Montserrat Arnan, Cerrano, Marco, Lopez, Patricia Font, Zeidner, Joshua F., Campelo, Maria Diez, Graux, Carlos, Liesveld, Jane, Selleslag, Dominik, Tzvetkov, Nikolay, Fram, Robert J., Zhao, Dan, Bell, Jill, Friedlander, Sharon, Faller, Douglas V., and Adès, Lionel

Published
2021
Full Text
View/download PDF

25. Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.

Author

Johnson, Steven M., Haberberger, James, Galeotti, Jonathan, Ramkissoon, Lori, Coombs, Catherine C., Richardson, Daniel R., Foster, Matthew C., Duncan, Daniel, Montgomery, Nathan D., Ferguson, Naomi L., and Zeidner, Joshua F.

Subjects
GENOMICS, TUMORS, MOLECULAR genetics, MYELOPROLIFERATIVE neoplasms, MYELOID leukemia
Abstract

A large-scale genomic analysis of patients with ASXL1-mutated myeloid disease has not been performed to date. We reviewed comprehensive genomic profiling results from 6043 adults to characterize clinicopathologic features and co-mutation patterns by ASXL1 mutation status. ASXL1 mutations occurred in 1414 patients (23%). Mutation co-occurrence testing revealed strong co-occurrence (p < 0.01) between mutations in ASXL1 and nine genes (SRSF2, U2AF1, RUNX1, SETBP1, EZH2, STAG2, CUX1, CSF3R, CBL). Further analysis of patients with these co-mutations yielded several novel findings. Co-mutation patterns supported that ASXL1/SF3B1 co-mutation may be biologically distinct from ASXL1/non-SF3B1 spliceosome co-mutation. In AML, ASXL1/SRSF2 co-mutated patients frequently harbored STAG2 mutations (42%), which were dependent on the presence of both ASXL1 and SRSF2 mutation (p < 0.05). STAG2 and SETBP1 mutations were also exclusive in ASXL1/SRSF2 co-mutated patients and associated with divergent chronic myeloid phenotypes. Our findings support that certain multi-mutant genotypes may be biologically relevant in ASXL1-mutated myeloid disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Data from Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Author

Zeidner, Joshua F., primary, Vincent, Benjamin G., primary, Ivanova, Anastasia, primary, Moore, Dominic, primary, McKinnon, Karen P., primary, Wilkinson, Alec D., primary, Mukhopadhyay, Rupkatha, primary, Mazziotta, Francesco, primary, Knaus, Hanna A., primary, Foster, Matthew C., primary, Coombs, Catherine C., primary, Jamieson, Katarzyna, primary, Van Deventer, Hendrik, primary, Webster, Jonathan A., primary, Prince, Gabrielle T., primary, DeZern, Amy E., primary, Smith, B. Douglas, primary, Levis, Mark J., primary, Montgomery, Nathan D., primary, Luznik, Leo, primary, Serody, Jonathan S., primary, and Gojo, Ivana, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Methods from Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Author

Zeidner, Joshua F., primary, Vincent, Benjamin G., primary, Ivanova, Anastasia, primary, Moore, Dominic, primary, McKinnon, Karen P., primary, Wilkinson, Alec D., primary, Mukhopadhyay, Rupkatha, primary, Mazziotta, Francesco, primary, Knaus, Hanna A., primary, Foster, Matthew C., primary, Coombs, Catherine C., primary, Jamieson, Katarzyna, primary, Van Deventer, Hendrik, primary, Webster, Jonathan A., primary, Prince, Gabrielle T., primary, DeZern, Amy E., primary, Smith, B. Douglas, primary, Levis, Mark J., primary, Montgomery, Nathan D., primary, Luznik, Leo, primary, Serody, Jonathan S., primary, and Gojo, Ivana, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Materials, Figures and Tables from A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Author

Zeidan, Amer M., primary, Knaus, Hanna A., primary, Robinson, Tara M., primary, Towlerton, Andrea M.H., primary, Warren, Edus H., primary, Zeidner, Joshua F., primary, Blackford, Amanda L., primary, Duffield, Amy S., primary, Rizzieri, David, primary, Frattini, Mark G., primary, Levy, Yair M., primary, Schroeder, Mark A., primary, Ferguson, Anna, primary, Sheldon, Katherine E., primary, DeZern, Amy E., primary, Gojo, Ivana, primary, Gore, Steven D., primary, Streicher, Howard, primary, Luznik, Leo, primary, and Smith, B. Douglas, primary

Published
2023
Full Text
View/download PDF

30. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

Author

Sallman, David A., primary, Al Malki, Monzr M., additional, Asch, Adam S., additional, Wang, Eunice S., additional, Jurcic, Joseph G., additional, Bradley, Terrence J., additional, Flinn, Ian W., additional, Pollyea, Daniel A., additional, Kambhampati, Suman, additional, Tanaka, Tiffany N., additional, Zeidner, Joshua F., additional, Garcia-Manero, Guillermo, additional, Jeyakumar, Deepa, additional, Komrokji, Rami, additional, Lancet, Jeffrey, additional, Kantarjian, Hagop M., additional, Gu, Lin, additional, Zhang, Yajia, additional, Tan, Anderson, additional, Chao, Mark, additional, O'Hear, Carol, additional, Ramsingh, Giridharan, additional, Lal, Indu, additional, Vyas, Paresh, additional, and Daver, Naval G., additional

Published
2023
Full Text
View/download PDF

34. Myeloid Malignancies

Author

Zeidner, Joshua F., primary, Roy, Darshan, additional, Perl, Alexander, additional, and Gojo, Ivana, additional

Published
2018
Full Text
View/download PDF

37. A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)

Author

Zeidner, Joshua F., primary, Foster, Matthew C., additional, Johnson, Mary, additional, Huang, Ying, additional, Swords, Ronan T., additional, Stein, Eytan, additional, Foran, James M., additional, Baer, Maria R., additional, Stock, Wendy, additional, Madanat, Yazan F., additional, Kovacsovics, Tibor, additional, Olin, Rebecca L., additional, Blum, William G., additional, Schiller, Gary J., additional, Lin, Tara L., additional, Redner, Robert L., additional, Al-Mansour, Zeina, additional, Curran, Emily K, additional, Heerema, Nyla A., additional, Martycz, Molly, additional, Rosenberg, Leonard, additional, Marcus, Sonja, additional, Yocum, Ashley O., additional, Chen, Timothy, additional, Stefanos, Mona, additional, Druggan, Franchesca, additional, Burd, Amy, additional, Levine, Ross L., additional, Druker, Brian J., additional, Borate, Uma, additional, Byrd, John C., additional, and Mims, Alice S., additional

Published
2022
Full Text
View/download PDF

39. A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Author

Cashen, Amanda F., primary, Liu, Hongtao, additional, Al Malki, Monzr M., additional, Zeidner, Joshua F., additional, Foster, Matthew C., additional, Pannunzio, Angela, additional, Ramsey, Brett, additional, Baughman, Jan, additional, Muth, John, additional, Bakkacha, Ouiam, additional, McNulty, Eileen, additional, Jacobs, Kenneth, additional, Davidson-Moncada, Jan K, additional, and Wei, Andrew H, additional

Published
2022
Full Text
View/download PDF

40. A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Author

Bewersdorf, Jan Philipp, primary, Shallis, Rory Michael, additional, Sharon, Elad, additional, Caldwell, Anne, additional, Wei, Wei, additional, Yacoub, Abdulraheem, additional, Madanat, Yazan F., additional, Zeidner, Joshua F., additional, Altman, Jessica K., additional, Odenike, Olatoyosi, additional, Yerrabothala, Swaroopa, additional, Kovacsovics, Tibor, additional, Podoltsev, Nikolai A., additional, Halene, Stephanie, additional, Little, Richard F., additional, Piekarz, Richard, additional, Gore, Steven D., additional, Kim, Tae Kon, additional, and Zeidan, Amer M., additional

Published
2022
Full Text
View/download PDF

41. Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Author

Wolach, Ofir, primary, Garcia, Jacqueline S., additional, Desai, Pinkal, additional, Vachhani, Pankit, additional, Zeidner, Joshua F., additional, Abedin, Sameem, additional, Sweet, Kendra, additional, Lai, Catherine, additional, Moshe, Yakir, additional, Pollyea, Daniel A., additional, Xavier, Marin, additional, Nachmias, Boaz, additional, Zuckerman, Tsila, additional, Lee, Sangmin, additional, Chen, Evan C., additional, Bathini, Srilakshmi, additional, Edwards, Wesleigh, additional, Bui, Cat N., additional, Cheng, Wei-Han, additional, Miller, Catherine, additional, Guerin, Annie, additional, Maitland, Jessica, additional, Ma, Esprit, additional, Montez, Melissa, additional, Grunspan, Moshe, additional, and Goldberg, Aaron D, additional

Published
2022
Full Text
View/download PDF

43. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Author

Xie, Zhuoer, primary, Smith, Alexandra, additional, Komrokji, Rami S., additional, Al Ali, Najla, additional, Patel, Anand Ashwin, additional, Saygin, Caner, additional, Zeidan, Amer M., additional, Bewersdorf, Jan Philipp, additional, Kishtagari, Ashwin, additional, Zeidner, Joshua F., additional, Coombs, Catherine C., additional, Madanat, Yazan F., additional, Foran, James M., additional, Badar, Talha, additional, Desai, Pinkal, additional, Tsai, Charlton, additional, Griffiths, Elizabeth A., additional, Al Malki, Monzr M., additional, Amanam, Idoroenyi, additional, Lai, Catherine, additional, Deeg, Joachim, additional, Ades, Lionel, additional, Arana Yi, Cecilia, additional, Osman, Afaf, additional, Dinner, Shira, additional, Abaza, Yasmin, additional, Chandhok, Namrata, additional, Soong, Deborah, additional, Taylor, Justin, additional, Brunner, Andrew M., additional, Carraway, Hetty E., additional, Singh, Abhay Singh, additional, Geyer, Susan M., additional, Padron, Eric, additional, Patnaik, Mrinal M.M., additional, Savona, Michael R., additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

47. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.

Author

Daver, Naval Guastad, primary, Vyas, Paresh, additional, Kambhampati, Suman, additional, Al Malki, Monzr M., additional, Larson, Richard A., additional, Asch, Adam Steven, additional, Mannis, Gabriel N., additional, Chai-Ho, Wanxing, additional, Tanaka, Tiffany N., additional, Bradley, Terrence J., additional, Jeyakumar, Deepa, additional, Wang, Eunice S., additional, Xing, Guan, additional, Chao, Mark, additional, Ramsingh, Giridharan, additional, Renard, Camille, additional, Lal, Indu, additional, Zeidner, Joshua F., additional, and Sallman, David Andrew, additional

Published
2022
Full Text
View/download PDF

48. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.

Author

Sallman, David Andrew, primary, Al Malki, Monzr M., additional, Asch, Adam Steven, additional, Wang, Eunice S., additional, Jurcic, Joseph G., additional, Bradley, Terrence J., additional, Flinn, Ian W., additional, Pollyea, Daniel Aaron, additional, Kambhampati, Suman, additional, Tanaka, Tiffany N., additional, Zeidner, Joshua F., additional, Garcia-Manero, Guillermo, additional, Jeyakumar, Deepa, additional, Gu, Lin, additional, Tan, Anderson, additional, Chao, Mark, additional, O'Hear, Carol Elaine, additional, Lal, Indu, additional, Vyas, Paresh, additional, and Daver, Naval Guastad, additional

Published
2022
Full Text
View/download PDF

50. Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains

Author

Woods, Justin D., primary, Zeidner, Joshua F., additional, Van Deventer, Hendrik W., additional, Jamieson, Katarzyna, additional, Matson, Melissa, additional, Zhang, Jack, additional, Pulley, William, additional, Brenizer, Tucker, additional, Muss, Hyman, additional, Nyrop, Kirsten A., additional, Vohra, Sanah N., additional, Deal, Allison M., additional, Ivanova, Anastasia, additional, and Foster, Matthew C., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results